



ESMO VIRTUAL PRECEPTORSHIP

22-23 JANUARY 2021

Co-Chairs

Fatima Cardoso, Portugal Rebecca A. Dent. Singapore

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME BREAST CANCER

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

22-23 January 2021

CO-CHAIRS:

Fatima Cardoso, Portugal Rebecca A. Dent, Singapore

SPEAKERS:

Prudence Francis, Australia Sung-Bae Kim, South Korea Soo Chin Lee, Singapore Paul N. Mainwaring, Australia Shani Paluch-Shimon, Israel Philip Poortmans, Belgium Veronique K. M. Tan, Singapore Janice W.-H. Tsang, Hong Kong Yoon Sim Yap, Singapore

LEARNING OBJECTIVES

- To learn about genetic testing and management of BRCA carriers
- To learn about the biology of breast cancer and its implications in the management of this disease
- To learn about the standard of care management of early, locally advanced and metastatic breast cancer in surgery, radiation therapy and systemic therapy
- To understand the crucial role of multidisciplinary care in the management of breast cancer

ACCREDITATION

The programme of this event has been accredited with **7 ESMO-MORA** category **1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For future details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from





ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland

Email: courses@esmo.org

www.esmo.org



COURSE STARTING TIME: AUSTRALIA (BRISBANE) 5 PM – AUSTRALIA (MELBOURNE) 6 PM BELGIUM 8 AM – ISRAEL 9 AM - PORTUGAL 7 AM SINGAPORE/HONG KONG 3 PM - SOUTH KOREA 4 PM

All timings in the programme are to be considered Singapore local time (GMT+8)

Friday, 22 January 2021

15:00-15:05 5'	Opening and welcome	
5'	Welcome and introduction	Fatima Cardoso, PT Rebecca A. Dent, SG
15:05-16:00 55'	MODULE 1 Biology	Chair/Moderator: Rebecca A. Dent, SG
25'	New breast cancer classification and new technologies: What's relevant in everyday practice?	Paul N. Mainwaring, AU
20'	Prognostic and predictive markers for breast cancer management	Fatima Cardoso, PT
10'	Discussion	Faculty
16:00-16:10	Break	
16:10-17:15 65'	MODULE 2 Local-regional treatment	Chair/Moderator: Fatima Cardoso, PT
25'	Principles of breast surgery / oncoplastic surgery	Veronique K. M. Tan, SG
25'	Principles of breast radiation therapy	Philip Poortmans, BE
15'	Discussion	Faculty
17:15-18:20 65'	MODULE 3 Triple Negative Breast Cancer (TNBC)	Chair/Moderator: Fatima Cardoso, PT
25'	(Neo-) adjuvant systemic therapy	Sung-Bae Kim, KR
25'	Systemic therapy for metastatic TNBC	Rebecca A. Dent, SG
15'	Discussion	Faculty
18:20-18:45 25'	MODULE 4 Clinical case discussion and Q&A	Chair/Moderator: Fatima Cardoso, PT Rebecca A. Dent, SG

Saturday, 23 January 2021

15:00-16:35 95'	MODULE 5 ER+/HER2 negative breast cancer Luminal BC	Chair/Moderator: Rebecca A. Dent, SG
25'	(Neo-) adjuvant endocrine therapy (pre and postmenopausal)	Prudence Francis, AU
25'	(Neo-) adjuvant chemotherapy for early ER+/HER2 negative BC	Janice WH. Tsang, HK
10'	Discussion	Faculty
25'	ET and targeted therapies for ER+/HER2 negative ABC	Yoon Sim Yap, SG
10'	Discussion	Faculty
16:35-16:45	Break	
16:45-17:25 40'	MODULE 6 Hereditary Breast Cancer	Chair/Moderator: Fatima Cardoso, PT
30'	Hereditary breast cancer	Shani Paluch-Shimon, IL
10'	Discussion	Faculty
17:25-18:30 65'	MODULE 7 HER2+ breast cancer	Chair/Moderator: Rebecca A. Dent, SG
25'	(Neo-) adjuvant systemic therapy	Soo Chin Lee, SG
25'	Systemic therapy for HER2+ advanced breast cancer	Fatima Cardoso, PT
15'	Discussion	Faculty
18:30-18:55 25'	MODULE 8 Clinical case discussion and Q&A	Chair/Moderator: Fatima Cardoso, PT Rebecca A. Dent, SG
18:55-19:00 5'	Closing remarks	Fatima Cardoso, PT Rebecca A. Dent, SG

Note: Each 10-minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion